Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 2/20 | 0.53 |
| ▸ | ABHD6 | Q9BV23 | 2/20 | 0.50 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.45 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.44 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.42 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.42 |
| ▸ | PDE4B | Q07343 | 3/20 | 0.41 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.40 |
| ▸ | DRD2 | P14416 | 1/20 | 0.40 |
| ▸ | HTR7 | P34969 | 1/20 | 0.40 |
| ▸ | STS | P08842 | 1/20 | 0.39 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | NAMPT | P43490 | 1/20 | 0.38 |
| ▸ | CFTR | P13569 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15754967 | 0.91 | NR1H2 (0.64) | NR1H2ESR2MAPK1ADORA1MEN1 | |
| SCHEMBL15754254 | 0.91 | NR1H2 (0.64) | NR1H2ESR2MAPK1ADORA1MEN1 | |
| SCHEMBL30468503 | 0.91 | NR1H2 (0.64) | NR1H2ESR2MAPK1ADORA1MEN1 | |
| SCHEMBL29516018 | 0.91 | NR1H2 (0.64) | NR1H2ESR2MAPK1ADORA1MEN1 | |
| SCHEMBL18759974 | 0.89 | NR1H2 (0.55) | NR1H2ABHD6ESR2MAPK1CHRM4 | |
| SCHEMBL18759911 | 0.89 | NR1H2 (0.55) | NR1H2ABHD6ESR2MAPK1CHRM4 | |
| SCHEMBL519943 | 0.86 | NR1H2 (0.54) | NR1H2ESR2MAPK1PDE4BCHRM4 | |
| SCHEMBL28375214 | 0.85 | NR1H2 (0.50) | NR1H2ABHD6HDAC1ESR2MAPK1 | |
| SCHEMBL24761120 | 0.84 | ABHD6 (0.51) | NR1H2ABHD6HDAC1ESR2MAPK1 | |
| SCHEMBL5436948 | 0.84 | NR1H2 (0.41) | NR1H2ABHD6ESR2MAPK1PDE4B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106459007-B | Pyrimidine-2, 4-diamine derivatives and pharmaceutical compositions for anticancer containing the same as the active ingredient | 韩国化学研究院 | 2020-02-28 | — | — | CN | disclosed |
| US-10053458-B2 | Pyrimidine-2,4-diamine derivative and anticancer pharmaceutical composition comprising same as effective ingredient | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2018-08-21 | — | — | US | disclosed |
| US-20170145007-A1 | PYRIMIDINE-2,4-DIAMINE DERIVATIVE AND ANTICANCER PHARMACEUTICAL COMPOSITION COMPRISING SAME AS EFFECTIVE INGREDIENT | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2017-05-25 | — | — | US | disclosed |
| EP-3159338-A2 | PYRIMIDINE-2,4-DIAMINE DERIVATIVE AND ANTICANCER PHARMACEUTICAL COMPOSITION COMPRISING SAME AS EFFECTIVE INGREDIENT | Korea Research Institute of Chemical Technology (KR) | 2017-04-26 | — | — | EP | disclosed |
| EP-2376491-B1 | PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS | CEPHALON INC (US) | 2015-03-04 | — | — | EP | disclosed |
| US-8471005-B2 | Pyrrolotriazines as ALK and JAK2 inhibitors | CEPHALON, INC. (US) | 2013-06-25 | — | — | US | disclosed |
| US-20120028919-A1 | PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS | CEPHALON, INC. (US) | 2012-02-02 | — | — | US | disclosed |
| EP-2376491-A1 | PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS | Cephalon, Inc. (US) | 2011-10-19 | — | — | EP | disclosed |
| WO-2010071885-A1 | PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS | CEPHALON, INC. (US) | 2010-06-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170145007-A1 | PYRIMIDINE-2,4-DIAMINE DERIVATIVE AND ANTICANCER PHARMACEUTICAL COMPOSITION COMPRISING SAME AS EFFECTIVE INGREDIENT | ALK, NPM1, ETV6 | NR1H2 3277/4885ABHD6 1782/4885HDAC1 3428/4885 |
| US-10053458-B2 | Pyrimidine-2,4-diamine derivative and anticancer pharmaceutical composition comprising same as effective ingredient | ALK, NPM1, ETV6 | NR1H2 3277/4885ABHD6 1782/4885HDAC1 3428/4885 |
| US-20120028919-A1 | PYRROLOTRIAZINES AS ALK AND JAK2 INHIBITORS | JAK2, ALK, ABL1 | NR1H2 3126/4885ABHD6 2234/4885HDAC1 811/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.